The role of interleukin‐10 promoter polymorphisms in primary Sjögren's syndrome

References

• Manthorpe R., Bredberg A., Henriksson G., Larsson A. Progress and regression within primary Sjögren's syndrome. Scand J Rheumatol 2006; 35: 1–6
   PubMed Web of Science ®Google Scholar
• Itoh K., Hirohata S. The role of IL‐10 in human B cell activation, proliferation, and differentiation. J Immunol 1995; 154: 4341–50
   PubMed Web of Science ®Google Scholar
• Hummelshoj L., Ryder L. P., Poulsen L. K. The role of the interleukin‐10 subfamily members in immunoglobulin production by human B cells. Scand J Immunol 2006; 64: 40–7
   PubMed Web of Science ®Google Scholar
• Halse A., Tengner P., Wahren‐Herlenius M., Haga H., Jonsson R. Increased frequency of cells secreting interleukin‐6 and interleukin‐10 in peripheral blood of patients with primary Sjögren's syndrome. Scand J Immunol 1999; 49: 533–8
   PubMed Web of Science ®Google Scholar
• Bertorello R., Cordone M. P., Contini P., Rossi P., Indiveri F., Puppo F., et al. Increased levels of interleukin‐10 in saliva of Sjögren's syndrome patients. Correlation with disease activity. Clin Exp Med 2004; 4: 148–51
   PubMed Web of Science ®Google Scholar
• Gibson A. W., Edberg J. C., Wu J., Westendorp R. G., Huizinga T. W., Kimberly R. P. Novel single nucleotide polymorphisms in the distal IL‐10 promoter affect IL‐10 production and enhance the risk of systemic lupus erythematosus. J Immunol 2001; 166: 3915–22
   PubMed Web of Science ®Google Scholar
• Westendorp R. G., Langermans J. A., Huizinga T. W., Elouali A. H., Verweij C. L., Boomsma D. I., et al. Genetic influence on cytokine production and fatal meningococcal disease. Lancet 1997; 349: 170–3
   PubMed Web of Science ®Google Scholar
• Crawley E., Kay R., Sillibourne J., Patel P., Hutchinson I., Woo P. Polymorphic haplotypes of the interleukin‐10 5′ flanking region determine variable interleukin‐10 transcription and are associated with particular phenotypes of juvenile rheumatoid arthritis. Arthritis Rheum 1999; 42: 1101–8
   PubMed Web of Science ®Google Scholar
• Eskdale J., Gallagher G., Verweij C. L., Keijsers V., Westendorp R. G., Huizinga T. W. Interleukin 10 secretion in relation to human IL‐10 locus haplotypes. Proc Natl Acad Sci USA 1998; 95: 9465–70
   PubMed Web of Science ®Google Scholar
• Turner D. M., Williams D. M., Sankaran D., Lazarus M., Sinnott P. J., Hutchinson I. V. An investigation of polymorphism in the interleukin‐10 gene promoter. Eur J Immunogenet 1997; 24: 1–8
   PubMedGoogle Scholar
• Gottenberg J. E., Busson M., Loiseau P., Dourche M., Cohen‐Solal J., Lepage V., et al. Association of transforming growth factor beta1 and tumor necrosis factor alpha polymorphisms with anti‐SSB/La antibody secretion in patients with primary Sjögren's syndrome. Arthritis Rheum 2004; 50: 570–80
   PubMed Web of Science ®Google Scholar
• Font J., Garcia‐Carrasco M., Ramos‐Casals M., Aldea A. I., Cervera R., Ingelmo M., et al. The role of interleukin‐10 promoter polymorphisms in the clinical expression of primary Sjögren's syndrome. Rheumatology (Oxford) 2002; 41: 1025–30
   PubMed Web of Science ®Google Scholar
• Marka M., Bessenyei B., Zeher M., Semsei I. IL‐10 promoter –1082 polymorphism is associated with elevated IL‐10 levels in control subjects but does not explain elevated plasma IL‐10 observed in Sjögren's syndrome in a Hungarian cohort. Scand J Immunol 2005; 62: 474–80
   PubMed Web of Science ®Google Scholar
• Origuchi T., Kawasaki E., Ide A., Kamachi M., Tanaka F., Ida H., et al. Correlation between interleukin 10 gene promoter region polymorphisms and clinical manifestations in Japanese patients with Sjögren's syndrome. Ann Rheum Dis 2003; 62: 1117–18
   PubMed Web of Science ®Google Scholar
• Hulkkonen J., Pertovaara M., Antonen J., Lahdenpohja N., Pasternack A., Hurme M. Genetic association between interleukin‐10 promoter region polymorphisms and primary Sjögren's syndrome. Arthritis Rheum 2001; 44: 176–9
   PubMed Web of Science ®Google Scholar
• Rischmueller M., Limaye V., Lester S., Downie‐Doyle S., Pile K., Bardy P., et al. Polymorphisms of the interleukin 10 gene promoter are not associated with anti‐Ro autoantibodies in primary Sjögren's syndrome. J Rheumatol 2000; 27: 2945–6
   PubMedGoogle Scholar
• D'Alfonso S., Rampi M., Rolando V., Giordano M., Momigliano‐Richiardi P. New polymorphisms in the IL‐10 promoter region. Genes Immunity 2000; 1: 231–3
   PubMedGoogle Scholar
• Eskdale J., Gallagher G. A polymorphic dinucleotide repeat in the human IL‐10 promoter. Immunogenetics 1995; 42: 444–5
   PubMedGoogle Scholar
• Eskdale J., Kube D., Gallagher G. A second polymorphic dinucleotide repeat in the 5′ flanking region of the human IL10 gene. Immunogenetics 1996; 45: 82–3
   PubMedGoogle Scholar
• Mormann M., Rieth H., Hua T. D., Assohou C., Roupelieva M., Hu S. L., et al. Mosaics of gene variations in the interleukin‐10 gene promoter affect interleukin‐10 production depending on the stimulation used. Genes Immunity 2004; 5: 246–55
   PubMed Web of Science ®Google Scholar
• D'Alfonso S., Giordano M., Mellai M., Lanceni M., Barizzone N., Marchini M., et al. Association tests with systemic lupus erythematosus (SLE) of IL10 markers indicate a direct involvement of a CA repeat in the 5′ regulatory region. Genes Immun 2002; 3: 454–63
   PubMed Web of Science ®Google Scholar
• Eskdale J., McNicholl J., Wordsworth P., Jonas B., Huizinga T., Field M., et al. Interleukin‐10 microsatellite polymorphisms and IL‐10 locus alleles in rheumatoid arthritis susceptibility. Lancet 1998; 352: 1282–3
   PubMed Web of Science ®Google Scholar
• Vitali C., Bombardieri S., Jonsson R., Moutsopoulos H. M., Alexander E. L., Carsons S. E., et al. Classification criteria for Sjögren's syndrome: a revised version of the European criteria proposed by the American–European Consensus Group. Ann Rheum Dis 2002; 61: 554–8
   PubMed Web of Science ®Google Scholar
• Kabasakal Y., Kitapcioglu G., Turk T., Oder G., Durusoy R., Mete N., et al. The prevalence of Sjögren's syndrome in adult women. Scand J Rheumatol 2006; 35: 379–83
   PubMed Web of Science ®Google Scholar
• Assmann G., Schulte H. Relation of high‐density lipoprotein cholesterol and triglycerides to incidence of atherosclerotic coronary artery disease (the PROCAM experience). Prospective Cardiovascular Munster study. Am J Cardiol 1992; 70: 733–7
   PubMed Web of Science ®Google Scholar
• Higuchi R. Simple and rapid preparation of samples for PCR. PCR technology. Principles and applications for DNA amplification, H. A Ehrlich. Stockton Press, New York 1989; 31–8
   Google Scholar
• Sanger F., Nicklein S., Coulson A. R. DNA sequencing with chain terminating inhibitors 5467. Proc Natl Acad Sci USA 1977; 74: 5463–7
   PubMed Web of Science ®Google Scholar
• Schotte H., Schluter B., Rust S., Assmann G., Domschke W., Gaubitz M. Interleukin‐6 promoter polymorphism (–174 G/C) in Caucasian German patients with systemic lupus erythematosus. Rheumatology (Oxford) 2001; 40: 393–400
   PubMed Web of Science ®Google Scholar
• Schotte H., Schluter B., Drynda S., Willeke P., Tidow N., Assmann G., et al. Interleukin 10 promoter microsatellite polymorphisms are associated with response to long‐term treatment with etanercept in patients with rheumatoid arthritis. Ann Rheum Dis 2005; 64: 575–81
   PubMed Web of Science ®Google Scholar
• Schotte H., Gaubitz M., Willeke P., Tidow N., Assmann G., Domschke W., et al. Interleukin‐10 promoter microsatellite polymorphisms in systemic lupus erythematosus: association with the anti‐Sm immune response. Rheumatology (Oxford) 2004; 43: 1357–63
   PubMedGoogle Scholar
• Sham P. C., Curtis D. Monte Carlo tests for associations between disease and alleles at highly polymorphic loci. Ann Hum Genet 1995; 59: 97–105
   PubMed Web of Science ®Google Scholar
• Riyazi N., Kurreeman F. A., Huizinga T. W., Dekker F. W., Stoeken‐Rijsbergen G., Kloppenburg M. The role of interleukin 10 promoter polymorphisms in the susceptibility of distal interphalangeal osteoarthritis. J Rheumatol 2005; 32: 1571–5
   PubMed Web of Science ®Google Scholar
• Eskdale J., Keijsers V., Huizinga T., Gallagher G. Microsatellite alleles and single nucleotide polymorphisms (SNP) combine to form four major haplotype families at the human interleukin‐10 (IL‐10) locus. Genes Immun 1999; 1: 151–5
   PubMed Web of Science ®Google Scholar
• Anaya J. M., Correa P. A., Herrera M., Eskdale J., Gallagher G. Interleukin 10 (IL‐10) influences autoimmune response in primary Sjögren's syndrome and is linked to IL‐10 gene polymorphism. J Rheumatol 2002; 29: 1874–6
   PubMed Web of Science ®Google Scholar
• Moore K. W., de Waal M. R., Coffman R. L., O'Garra A. Interleukin‐10 and the interleukin‐10 receptor. Annu Rev Immunol 2001; 19: 683–765
   PubMed Web of Science ®Google Scholar
• Llorente L., Zou W., Levy Y., Richaud‐Patin Y., Wijdenes J., Alcocer‐Varela J., et al. Role of interleukin 10 in the B lymphocyte hyperactivity and autoantibody production of human systemic lupus erythematosus. J Exp Med 1995; 181: 839–44
   PubMed Web of Science ®Google Scholar
• Kurreeman F. A., Schonkeren J. J., Heijmans B. T., Toes R. E., Huizinga T. W. Transcription of the IL10 gene reveals allele‐specific regulation at the mRNA level. Hum Mol Genet 2004; 13: 1755–62
   PubMed Web of Science ®Google Scholar
• Huizinga T. W., Keijsers V., Yanni G., Hall M., Ramage W., Lanchbury J., et al. Are differences in interleukin 10 production associated with joint damage?. Rheumatology (Oxford) 2000; 39: 1180–8
   PubMed Web of Science ®Google Scholar
• Grondal G., Kristjansdottir H., Gunnlaugsdottir B., Arnason A., Lundberg I., Klareskog L., et al. Increased number of interleukin‐10‐producing cells in systemic lupus erythematosus patients and their first‐degree relatives and spouses in Icelandic multicase families. Arthritis Rheum 1999; 42: 1649–54
   PubMed Web of Science ®Google Scholar
• Gottenberg J. E., Loiseau P., Azarian M., Chen C., Cagnard N., Hachulla E., et al. CTLA‐4 +49A/G and CT60 gene polymorphisms in primary Sjögren syndrome. Arthritis Res Ther 2007; 9: R24
   PubMed Web of Science ®Google Scholar
• Mok C. C., Lanchbury J. S., Chan D. W., Lau C. S. Interleukin‐10 promoter polymorphisms in Southern Chinese patients with systemic lupus erythematosus. Arthritis Rheum 1998; 41: 1090–5
   PubMed Web of Science ®Google Scholar
• Rueda B., Roibas B., Martin J., Gonzalez‐Gay M. A. Influence of interleukin 10 promoter polymorphisms in susceptibility to giant cell arteritis in Northwestern Spain. J Rheumatol 2007; 34: 1535–9
   PubMed Web of Science ®Google Scholar
• Sordet C., Gottenberg J. E., Goetz J., Bengoufa D., Humbel R. L., Mariette X., et al. Anti‐{alpha}‐fodrin autoantibodies are not useful diagnostic markers of primary Sjögren's syndrome. Ann Rheum Dis 2005; 64: 1244–5
   PubMedGoogle Scholar
• Zandbelt M. M., Vogelzangs J., Van De Putte L. B., Van Venrooij W. J., Van Den Hoogen F. H. Anti‐alpha‐fodrin antibodies do not add much to the diagnosis of Sjögren's syndrome. Arthritis Res Ther 2004; 6: R33–8
   Google Scholar
• Witte T., Matthias T., Arnett F. C., Peter H. H., Hartung K., Sachse C., et al. IgA and IgG autoantibodies against alpha‐fodrin as markers for Sjögren's syndrome. J Rheumatol 2000; 27: 2617–20
   PubMed Web of Science ®Google Scholar
• Witte T., Matthias T., Oppermann M., Helmke K., Peter H. H., Schmidt R. E., et al. Prevalence of antibodies against alpha‐fodrin in Sjögren's syndrome: comparison of 2 sets of classification criteria. J Rheumatol 2003; 30: 2157–9
   PubMedGoogle Scholar
• Willeke P., Gaubitz M., Schotte H., Becker H., Mickholz E., Domschke W., et al. Clinical and immunological characteristics of patients with Sjögren's syndrome in relation to alpha‐fodrin antibodies. Rheumatology 2007; 46: 479–83
   PubMedGoogle Scholar